An interventional study of MRI and EEG in Autism Spectrum Disorder, sponsored by University Hospital, Tours. Recruiting at 3 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by University Hospital, Tours · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Autistic Disorder with a site in France — 10 open to participants now, 10 under way, 1 of them phase 3. Autistic Disorder · France.
Among the 50 studies in Autistic Disorder with a site in France, this one is the 16th largest by planned enrollment of the 37 interventional ones that give a count, is one of 5 that started in 2023, is one of 26 with no phase, and was the 40th registered.
1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.
Browse Autistic Disorder studies →10 of the 50 studies in Autistic Disorder with a site in France are open now. Recruiting first, the newest first:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in France, United States, Australia and 8 more countries
Ages 5–17
University Hospital, Brest · Sites in France
Ages up to 24
University Hospital, Grenoble · Sites in France
Ages 18–50 · Healthy volunteers
Centre Hospitalier Intercommunal Robert Ballanger · Sites in France
Ages 3–15
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages 24 mo–70 yrs · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 184 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 144 (78%) stop at 75 or younger; 150 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 78 is above the median of 50 across 814 interventional studies indexed under Autistic Disorder.
Median enrollment 60 across the 37 interventional studies, 103 across the 13 observational. Of the 32 that completed or were terminated, 4 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 50 have an industry lead sponsor. The 10 most frequent:
University Hospital, Tours is the lead sponsor of 309 studies on the registry; 81 are open to participants now.
University Hospital, Tours has 5 studies filed under Autistic Disorder — fewer than ten, so there is no comparison to draw.
1 of the studies in Autistic Disorder with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06443320Centre Hospitalier Intercommunal Robert BallangerEvaluation of the Videodrama Therapeutic Device for Children with Autism Spectrum Disorders | 2027-03-04 |
Add it to your calendar (.ics) → With an account.
Among the 50 studies in Autistic Disorder with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An MRI Study in Subjects with Autism Spectrum Disorder and Subjects with Food Addictive Disorder compared to healthy volunteers.
An MRI Study in Subjects with Autism Spectrum Disorder and Subjects with Food Addictive Disorder compared to healthy volunteers, where pathophysiology common to both disorders, based on a dysfunction of the reward system. The project we propose aims to explore the neural networks underlying these alterations in patients suffering from autism or addictive disorder.
1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.
This study's planned enrollment of 78 is above the median of 50 across 814 interventional studies indexed under Autistic Disorder.
Browse Autistic Disorder studies →University Hospital, Tours is the lead sponsor of 309 studies on the registry; 81 are open to participants now.
Compared within Autistic Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autism Spectrum Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Arm A ˗ Concerning ASD patients: Adult carrying the diagnosis of ASD (, ADOS, ADI-R criteria)
Arm B ˗ Concerning FAD patients: Adult diagnosed with FA presenting with food addiction (DSM-5, YFAS 2.0, BES >= 18 criteria).
Arm C ˗ Concerning healthy volunteers : Adult with no neurological and psychiatric history , absence of progressive somatic pathologies or with vital risk.
For all participants:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Characterized by two main diagnostic criteria: a socio-emotional deficit via a defect in communication and social reciprocity, and a behavioral deficit which manifests itself in repetitive behavioral patterns (stereotypes), restricted interests and/or activities.
Diagnostic Test: MRI · Diagnostic Test: EEG
Characterized by regroup substance use disorders and behavioral addictions, are characterized in particular by the repeated occurrence of compulsive behavior and impaired social functioning
Diagnostic Test: MRI · Diagnostic Test: EEG
Adult without neurological and psychiatric history, absence of progressive somatic pathologies or with vital risk.
Diagnostic Test: MRI · Diagnostic Test: EEG
an fMRI measurement of the BOLD physiological signal for sensory responses
Also known as: Functionnal MRI
These tests, through videos with a social or non-social content (human presence or absence on the stereoscopic projection), will allow us to study two types of sensorialities (visual and interoceptive). Thus, it will be possible to obtain inter- and exteroceptive profiles of the participants, a direct reflection of the processing of the internal bodily sensations of the body.
Also known as: Electro Encephalography
Blood Oxygene Level Dependent (BOLD) MRI signal
Measurement in fMRI of the BOLD signal for each condition (interest, addiction, social) will be carried out in order to highlight the possible alterations of the reward system, in particular at the level of the striatum in terms of cerebral activation for each of the groups of subjects. (FAD, ASD and HV).
Time frame: At inclusion
Tolerance to an MRI examination for FAD with overweight or obesity
For the tolerance to an MRI examination for FAD with overweight or obesity: feedback on their experience in MRI.
Time frame: At inclusion
Regulation of sensory, an fMRI measurement of the BOLD physiological signal for sensory responses (sensory block) in terms of brain activation in patients
Regulation of sensory, an fMRI measurement of the BOLD physiological signal for sensory responses (sensory block) in terms of brain activation in patients with FAD compared to ASD subjects and healthy volunteers.
Time frame: At inclusion
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Jul 2028, 60 months after the start.
Of 355 non-industry interventional studies with no phase under Autistic Disorder, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 60 months is above that.
Counting every sponsor, half of 367 studies reached it within 26 months; a quarter within 13 and three quarters within 50.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Jul 2026 → Jul 2028 and completion Jan 2027 → Jul 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.